| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/17/2006 | CA2152284C Condensed benzo(d)isoxazole derivatives and their use as psychoactive agents |
| 01/17/2006 | CA2147567C Improvements in platinum complexes |
| 01/17/2006 | CA2138930C Substituted benzenesulfonylureas and -thioureas, preparation processes and possible uses of pharmaceutical preparations based on these compounds |
| 01/17/2006 | CA2131495C Double-layered oxcarbazepine tablets |
| 01/17/2006 | CA2129079C Orally administrable cholesterol lowering agent |
| 01/17/2006 | CA2118812C 5-ht4 receptor antagonists |
| 01/16/2006 | CA2512059A1 Transdermal drug delivery formulations with optimal amounts of vasodilators therein |
| 01/12/2006 | WO2006005057A2 Muscarinic acetylcholine receptor antagonists |
| 01/12/2006 | WO2006005017A2 Oral composition comprising carbamylating agent |
| 01/12/2006 | WO2006004937A2 Non-imidazole tertiary amines as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other cns disorders |
| 01/12/2006 | WO2006004931A2 Substituted azepine derivatives as serotonin receptor modulators |
| 01/12/2006 | WO2006004903A2 1,2-bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof |
| 01/12/2006 | WO2006004884A2 Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors |
| 01/12/2006 | WO2006004833A2 Pyrrolotriazine kinase inhibitors |
| 01/12/2006 | WO2006004795A2 Angiogenesis inhibitors |
| 01/12/2006 | WO2006004793A2 Hetero isonipecotic modulators of vanilloid vr1 receptor |
| 01/12/2006 | WO2006004792A1 Drug-delivery stent formulations for restenosis and vulnerable plaque |
| 01/12/2006 | WO2006004774A2 Laulimalide analogues as therapeutic agents |
| 01/12/2006 | WO2006004759A2 Topical compositions for anti-aging |
| 01/12/2006 | WO2006004757A2 Topical formulations for treating allergic diseases |
| 01/12/2006 | WO2006004738A2 Methods to inhibit histone acetyltransferase using glycosaminoglycans |
| 01/12/2006 | WO2006004724A2 A method for preparing pyrrolotriazine compounds |
| 01/12/2006 | WO2006004722A2 Compositions and methods for selectively activating human sirtuins |
| 01/12/2006 | WO2006004702A1 Condensed triazoles and indazoles useful in treating citokines mediated diseases and other diseases |
| 01/12/2006 | WO2006004636A2 Fused heterocyclic kinase inhibitors |
| 01/12/2006 | WO2006004622A2 Inhibition of bid-induced cell-death using small organic molecules |
| 01/12/2006 | WO2006004613A2 Guanylhydrazone salts, compositions, processes of making and methods of using |
| 01/12/2006 | WO2006004582A1 Compositions and methods for the treatment of radiation burns and other traumatic skin conditions |
| 01/12/2006 | WO2006004574A2 Method for using gamma cyclodextrin to control blood glucose and insulin secretion |
| 01/12/2006 | WO2006004458A1 Biologically active astaxanthin-containing agent |
| 01/12/2006 | WO2006004115A1 Remedy for hyperactive bladder |
| 01/12/2006 | WO2006003909A1 Fat combustion accelerator |
| 01/12/2006 | WO2006003676A1 A novel method to inhibit inflammation and tumor growth by tylophora alkaloids |
| 01/12/2006 | WO2006003518A2 6-phosphorylcholine-n-acetyl-d-galactosamine conjugate molecules and their use in vaccinal, therapeutic and diagnostic applications against bacterial infection of the respiratory tract |
| 01/12/2006 | WO2006003517A1 Combination therapies utilizing benzamide inhibitors of the p2x7 receptor |
| 01/12/2006 | WO2006003513A1 Method for preparing 5-`4-(2-hydroxy-ethyl)-3,5-dioxo-4,5-dihydro-3h-`1,2,4!-triazin-2-yl!benzamide derivatives with p2x7 inhibiting activity by reaction of the derivative unsubstituted in 4-position of the triazine with an oxiran in the presence of a lewis acid |
| 01/12/2006 | WO2006003500A1 Method for preparing 5-`4-(2-hydroxy-propyl)-3,5-dioxo-4,5-dihydro-3h`1,2,4!triazin-2-yl!-benzamide derivatives by deprotecting the hydroxyl-protected precursers |
| 01/12/2006 | WO2006003495A1 Substituted heteroaryl- and phenylsulfamoyl compounds |
| 01/12/2006 | WO2006003492A2 Compositions and methods for treating pathological infections |
| 01/12/2006 | WO2006003479A2 New pseudopolymorph of desloratadine formed with carbon dioxide |
| 01/12/2006 | WO2006003331A1 Flavonol-based medicine for treating and/or preventing endoprosthetic restenosis and atheromatous disease in coronary patients |
| 01/12/2006 | WO2006003299A1 Hydroalcoholic depigmentation gel comprising mequinol and adapalene |
| 01/12/2006 | WO2006003290A2 Sulphated depolymerised derivatives of exopolysaccharides (eps), preparation and uses thereof |
| 01/12/2006 | WO2006003289A2 Sulphated polysaccharide derivatives for modulating angiogenesis |
| 01/12/2006 | WO2006003276A1 Substituted indazoles, compositions containing same, preparation and use |
| 01/12/2006 | WO2006003152A1 GRANULES COMPRISING A ß-LACTAM ANTIBIOTIC |
| 01/12/2006 | WO2006003150A1 Substituted 2-alkyl quinazolinone derivatives as parp inhibitors |
| 01/12/2006 | WO2006003146A1 Quinazolinone derivatives as parp inhibitors |
| 01/12/2006 | WO2006003107A1 Use of malic acid glucosides as flavouring substances |
| 01/12/2006 | WO2006003078A1 Medicaments for inhalation comprising steroids and an anticholinergic |
| 01/12/2006 | WO2006003043A1 Oral antimicrobial pharmceutical compositions |
| 01/12/2006 | WO2006002971A2 Nucleic acids for the treatment of hmgb1-related pathologies |
| 01/12/2006 | WO2006002956A1 Piperidine derivatives and their use as glycine transporter inhibitors |
| 01/12/2006 | WO2006002927A2 Medium chain fatty acids applicable as anti-microbial agents |
| 01/12/2006 | WO2006002912A1 D-xylopyranosyl-substituted phenyls, medicaments containing said compounds, the use thereof, and methods for producing the same |
| 01/12/2006 | WO2006002908A1 Carbazole-derived pharmaceutical compositions |
| 01/12/2006 | WO2006002907A1 Use of steroid-derived pharmaceutical compositions for treating disorders relating to pathological processes in lipid rafts |
| 01/12/2006 | WO2006002887A1 Aqueous drink solution of indibulin (d-24851) and an organic acid |
| 01/12/2006 | WO2006002886A1 Oral dosage form safeguarded against abuse containing (1r, 2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol |
| 01/12/2006 | WO2006002883A1 Method for producing a solid dosage form, which is safeguarded against abuse, while using a planetary gear extruder |
| 01/12/2006 | WO2006002823A1 Use of substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines in the treatment of nausea and vomiting |
| 01/12/2006 | WO2006002698A1 Use of acetyl l-carnitine for the preparation of a medicine for the treatment of neuropathic pain in diabetic patients |
| 01/12/2006 | WO2006002506A1 Hydroxyamate-containing materials for the inhibition of matrix metalloproteinases |
| 01/12/2006 | WO2006002495A1 Prebiotic preparation |
| 01/12/2006 | WO2005119252A3 Modulators of gpr35 for the treatment of metabolic-related disorders |
| 01/12/2006 | WO2005117908A3 Triheterocyclic compounds compositions, and methods for treating cancer or viral diseases |
| 01/12/2006 | WO2005117847A3 Methods and compounds for the treatment of neoplasms |
| 01/12/2006 | WO2005113483A3 Levalbuterol hydrochloride polymorph a |
| 01/12/2006 | WO2005112914A3 Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease |
| 01/12/2006 | WO2005108378A3 Use of (4-alkylpiperazinyl) (phenyl) methanones in the treatment of alzheimer’s disease |
| 01/12/2006 | WO2005107706A3 Biodegradable intravitreal tyrosine kinase inhibitors implants |
| 01/12/2006 | WO2005105817A3 Coupling process for generating reactive boron containing derivatives of n-substituted pyrrole-2 carbonitriles to produce biaryls |
| 01/12/2006 | WO2005105081A3 Therapeutic formulations of desoxyepothilones |
| 01/12/2006 | WO2005105079A3 Novel imidazoles |
| 01/12/2006 | WO2005105074A3 Composition for treating or preventing cell degeneration using at least one molecule capable of maintaining adhesion molecule expression reversibility and vascular endothelium actin fibre polymerisation |
| 01/12/2006 | WO2005103037A3 Selected cgrp antagonists, methods for the production thereof, and use thereof as medicaments |
| 01/12/2006 | WO2005102308A3 Crystalline and amorphous forms of efaproxiral sodium |
| 01/12/2006 | WO2005102247A3 Multi-phase contraceptive preparation based on a natural estrogen |
| 01/12/2006 | WO2005099822A3 Reduction of drug / drug interactions with modafinil |
| 01/12/2006 | WO2005097730A3 Method of exchanging anions of tetraalkylammonium salts |
| 01/12/2006 | WO2005097618A3 Low dose therapy for treating viral infections |
| 01/12/2006 | WO2005097088A3 Inhibition of nuclear export as a treatment for cardiac hypertrophy and heart failure |
| 01/12/2006 | WO2005094810A3 Novel pharmaceutical compositions |
| 01/12/2006 | WO2005092066A3 Imidazole compounds |
| 01/12/2006 | WO2005089744A3 Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma |
| 01/12/2006 | WO2005087206A3 Cancer therapy comprising a nuclear receptor ligand and a hdac inhibitor |
| 01/12/2006 | WO2005084317A3 Dimeric small molecule potentiators of apoptosis |
| 01/12/2006 | WO2005082343A3 Amines and amides for the treatment of diseases |
| 01/12/2006 | WO2005080343A3 3-substituted 1,5-diphenylpyrazole derivatives useful as cb1 modulators |
| 01/12/2006 | WO2005079853A3 Soft gelatin capsule comprising omega-3 polyunsaturated fatty acid |
| 01/12/2006 | WO2005077902A3 Methods for the synthesis of pyridoxamine |
| 01/12/2006 | WO2005066115A3 Disubstituted chalcone oximes having rarϝ retinoid receptor antagonist activity |
| 01/12/2006 | WO2005065319A3 Generally linear effervescent oral fentanyl dosage form and methods of administering |
| 01/12/2006 | WO2005058362A3 Method for opening tight junctions comprising the use of jam-1, claudin-4 and occludin protein antagonists as well as sirna molecules |
| 01/12/2006 | WO2005051958A3 Particle-forming compositions containing fused pyrrolocarbazoles |
| 01/12/2006 | WO2005049027A3 Combinations useful for the treatment of neuronal disorders |
| 01/12/2006 | WO2005048928A3 Methods for treating viral infection |
| 01/12/2006 | WO2005044222A3 Oral formulations for 5-ht-receptor agonists, uses and methods of treatment employing the same |
| 01/12/2006 | WO2005037949A3 Aerosol formulations of butalbital, lorazepam, ipratropium, baclofen, morphine and scopolamine |
| 01/12/2006 | WO2005035731A3 Methods for treating diseases and conditions with inverse agonists and for screening for agents acting as inverse agonists |